ImmunityBio Inc. Among Tuesdayâs Worst-Performing Stocks Amid Market Turmoil
On Tuesday, we published an analysis detailing the 10 worst-performing stocks of the day, with a specific focus on how ImmunityBio Inc. (NASDAQ:IBRX) compares to others on this unfortunate list. The stock market experienced significant declines, a trend largely attributed to rising tensions regarding President Donald Trumpâs impending tariffs on China. The proposed tariffs could impose an astonishing 104-percent import tax on Chinese goods, leading to widespread concern among investors.
The main indices on Wall Street were hit hard, with the tech-heavy Nasdaq suffering the steepest decline of 2.15%. Following closely behind were the S&P 500, which saw a drop of 1.57%, and the Dow Jones Industrial Average, which fell by 0.84%. This broad market downturn was mirrored by the performance of ten companies that experienced hefty losses, one of which was ImmunityBio Inc.
In our analysis, we selected only those stocks boasting a market capitalization of at least $2 billion and trading volumes of $5 million to ensure a fair comparison of performance.
What Led to the Decline of ImmunityBio Inc. (IBRX) on Tuesday?
ImmunityBio Inc. continued a troubling trend on Tuesday, marking its fourth consecutive day of losses. The stock plummeted by 11.03%, closing at $2.42 per share. This decline occurred despite an announcement from the company regarding a significant financing round. ImmunityBio secured approximately $75 million in equity and warrants financing from a single institutional investor. If the warrants are fully exercised, the company expects to raise a total of $90 million.
This infusion of capital is intended to support ImmunityBioâs ongoing business operations and fulfill its capital needs. However, the market response was not favorable. Investors opted to liquidate their positions in light of prevailing economic uncertainties, which overshadowed the positive news of the financing deal.
The securities involved in this financing will be sold under the companyâs automatic shelf registration program. A final prospectus supplement is set to be filed with the U.S. Securities and Exchange Commission (SEC), which will provide further details about the offering and will be accessible on the SECâs website.
ImmunityBio is recognized as a vertically integrated biotechnology company focused on developing advanced therapies and vaccines designed to enhance the natural immune systemâs ability to combat cancers and infectious diseases. Despite its potential within the biotechnology field, ImmunityBio ranked 10th on our list of Tuesdayâs worst-performing stocks.
While we remain optimistic about ImmunityBio's long-term prospects, our analysis indicates that artificial intelligence (AI) stocks may offer a more enticing investment opportunity in the shorter term. For instance, one particular AI stock has shown remarkable resilience, increasing in value since the start of 2025, even as many popular AI stocks have collectively lost around 25% of their value. For those investors who are seeking promising AI stocks trading at under five times their earnings, we recommend checking out our detailed report highlighting the most affordable options available in this space.
